How to access Rystiggo from the UAE, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Emirati patient living with generalised myasthenia gravis (gMG) may receive a prescription for Rystiggo (rozanolixizumab-noli) from their treating neurologist or neuromuscular specialist. Rystiggo is FDA-approved for gMG in adult patients who are anti-acetylcholine receptor (AChR) antibody positive or anti-muscle-specific tyrosine kinase (MuSK) antibody positive, and it is manufactured by UCB. It is notable as one of the first FcRn antagonists with a specific MuSK-positive indication, an important advance because MuSK-positive gMG is a clinically distinct and often more severe subtype. Rystiggo is administered as a subcutaneous infusion. In the UAE, Rystiggo may not yet be broadly registered, which is why your neurologist may be navigating a named-patient import pathway with you.
This guide explains the legal pathway, what your physician needs to provide, typical timelines, and where Reserve Meds fits in.
Ask about Rystiggo in UAE
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Rystiggo is administered as a weekly subcutaneous infusion over 15 minutes for six weeks (one treatment cycle), with additional cycles initiated based on clinical response and symptom fluctuation. Eligibility typically requires confirmed AChR- or MuSK-antibody seropositivity, an MGFA clinical classification, and pre-treatment screening. Your treating neurologist confirms diagnosis, screening status, and the cycle plan per FDA labeling.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Rystiggo legally importable into the UAE?
Yes, through the UAE Ministry of Health and Prevention (MoHAP) named-patient import framework. The pathway allows an Emirati-licensed physician to request import of a medicine not broadly registered locally when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no locally registered alternative is clinically equivalent for the patient, (c) the physician takes clinical responsibility, and (d) chain of custody is documented through a licensed importing entity.
For Rystiggo specifically, the application benefits from the subcutaneous infusion route, it can be administered in a clinic or an infusion centre, and each session is brief.
How the pathway works, step by step
- Consultation with your treating neurologist. AChR or MuSK antibody confirmation, gMG clinical diagnosis, MGFA classification, and pre-treatment screening.
- Administration facility identification. The administering facility must be equipped for subcutaneous infusions and to manage any reaction.
- MoHAP named-patient application. Your physician files the application including clinical letter, patient identifier, and product details.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner.
- Cold-chain shipment. Rystiggo ships at 2-8°C with continuous temperature monitoring.
- Arrival and cycle administration. The licensed facility administers the six-weekly cycle; additional cycles per clinical response.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming gMG diagnosis, AChR or MuSK antibody positivity, MGFA class, and prior therapy history
- Verification of the UAE medical licence
- Identification of the administering facility
- Patient identifier
- Pre-treatment screening results and vaccination record
- Planned cycle schedule
Reserve Meds provides a physician documentation kit that bundles the templates MoHAP reviewers expect to see for FcRn-antagonist therapy.
Costs and timing
Medicine price: quote on request. You get a written quote for your case before you commit. International cold-chain logistics, MoHAP documentation, and coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake.
We give you a written timeline estimate for your case before you commit.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Rystiggo specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for MoHAP review.
- Logistics. Cold-chain, temperature-monitored shipment.
- Dedicated case lead. A named point of contact.
What we do not do: We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP named-patient framework with appropriate documentation.
How does Rystiggo compare with Vyvgart for gMG? Both are FcRn antagonists. Vyvgart is approved specifically for AChR-antibody-positive gMG and is administered IV (one hour) or as a Hytrulo subcutaneous formulation. Rystiggo is approved for both AChR-antibody- and MuSK-antibody-positive gMG and is administered as a weekly 15-minute subcutaneous infusion in six-week cycles. Patients with MuSK-positive disease often have Rystiggo specifically considered because of the broader approved label.
What about MuSK-positive myasthenia gravis? MuSK-positive gMG tends to have a more severe bulbar and respiratory phenotype and typically responds less well to conventional acetylcholinesterase inhibitors (pyridostigmine). The availability of an FcRn antagonist approved for MuSK-positive disease is clinically meaningful for this subgroup.
Will private insurance cover this? Cash-pay is the default. Some UAE private insurers reimburse gMG biologic therapy on escalated review; we supply documentation but do not process insurance claims directly.
Next step
For Rystiggo coordination in the UAE, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-23.
Abu Dhabi and Dubai
This guide covers the whole UAE, including Abu Dhabi and Dubai. At federal level, medicines are regulated by the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP). MOHAP also issues permits to import medicines for personal use. Hospitals, clinics and doctors are licensed by the health authority of their own emirate: the Department of Health Abu Dhabi (DoH) in Abu Dhabi, and the Dubai Health Authority (DHA) in Dubai.
In practice, the hospital that treats you follows the rules of its own emirate, so the paperwork is prepared for that hospital. Tell us which hospital or doctor is treating you, in Abu Dhabi, Dubai or another emirate, and we prepare the document pack for that route.
Sources: Department of Health Abu Dhabi; Dubai Health Authority, Health Regulation Sector; MOHAP, permit to import medicines for personal use; Simmons & Simmons, UAE pharmaceutical law and the Emirates Drug Establishment.
Frequently asked questions
How can I get Rystiggo in the UAE if it is not approved or available there?
Reserve Meds coordinates US-sourced Rystiggo for patients in the UAE through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for the UAE and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Rystiggo in the UAE through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Rystiggo. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in the UAE, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Rystiggo in the UAE through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Rystiggo to a patient in the UAE?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Rystiggo to your treating physician or hospital pharmacy in the UAE, with appropriate handling for the product.
How long does it take, and what does Rystiggo in the UAE cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Rystiggo in the UAE?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.